OREANDA-NEWS. The Argentinean authorities have approved Sputnik Lite as a standalone vaccine and as a revaccination product. This was reported by the Russian Direct Investment Fund (RDIF).

"The efficacy of the single-component Sputnik Light vaccine against the delta variant as a booster injection for other vaccines will be close to the efficacy against the delta variant of the Sputnik V vaccine - over 83% against infection and over 94% against hospitalisation,"- the RDIF said.

It added that Sputnik Lite could be used for revaccination after AstraZeneca, Sinopharm, Moderna and Cansino. "The data demonstrated a high safety profile for the use of Sputnik Lite in combination with all other vaccines,"- the Russian foundation said.

There are six vaccines in use in Argentina. These are Sputnik V, Covishield (from AstraZeneca), the Chinese Sinopharm and Cansino as well as Moderna and Pfizer.

In September, scientists from the University of Cordoba in Argentina conducted a study and found that a vaccine from the Gamaleya Research Institute was more effective against the delta strain than products from AstraZeneca and Sinopharm. People vaccinated with the Russian drug had the most antibodies.

One of the authors of the study, Sandra Gallego, noted that they were only assessing "the presence of neutralising antibodies". "But there are other types of response, such as cellular response. So there could be people who don't have antibodies, but they would have immune memory that would probably protect against the virus,"- she said.